The Europe DNA Plasmid Manufacturing Market is projected to grow from US$ 155.8 million in 2024 to approximately US$ 592.6 million by 2031, registering a compound annual growth rate (CAGR) of 21.2% from 2025 to 2031. Rising demand for gene therapies, mRNA vaccines, immunotherapies, and advanced biologics is strengthening Europe’s position as a major center for plasmid DNA manufacturing and biopharmaceutical innovation.<\/p>\n
The market encompasses the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany, the UK, and France are among the leading markets, supported by established biotechnology industries, advanced manufacturing infrastructure, and sustained investment in genetic research. The expansion of personalized medicine is also increasing demand for high-quality plasmid DNA used in therapies targeting genetic disorders, cancer, and infectious diseases.<\/p>\n
Europe’s stringent regulatory framework continues to influence plasmid DNA manufacturing standards, particularly for clinical and commercial applications. Manufacturers are investing in GMP-compliant capacity, process optimization, and quality control to address the increasingly complex requirements of cell and gene therapy developers. Collaboration between academic institutions, biotechnology companies, and manufacturing specialists is also improving plasmid yield, purity, scalability, and production timelines.<\/p>\n
BioNTech’s work in mRNA vaccine technology illustrates the strategic role of plasmid DNA in advanced therapeutic development. The company has completed construction of a proprietary plasmid DNA manufacturing facility in Marburg, Germany, designed to support clinical and commercial programs in cancer and infectious diseases. In Belgium, Catalent opened a commercial-scale plasmid DNA manufacturing facility in January 2023 at its European Center of Excellence for Cell Therapies in Gosselies, reinforcing regional production capacity.<\/p>\n
By product type, the Europe DNA Plasmid Manufacturing Market is segmented into GMP Grade and R&D Grade. GMP Grade accounted for the largest market share in 2024 as developers increased clinical development and commercialization activities. By application, the market includes Cell and Gene Therapy, DNA Vaccines, Immunotherapy, and other uses, with Cell and Gene Therapy expected to remain the dominant segment. Pharmaceutical and Biotechnology Companies are anticipated to represent the leading end-user category.<\/p>\n
Outsourcing is becoming a central market trend as biopharmaceutical companies seek scalable production without the capital expenditure required for in-house facilities. Specialized Contract Development and Manufacturing Organizations (CDMOs) provide GMP-compliant plasmid DNA services that can accelerate development, improve supply reliability, and support time-to-market objectives. Established participants include Aldevron, a Danaher company serving gene and cell therapy programs, and VGXI, a GeneOne Life Science subsidiary that uses proprietary Helix fermentation technology.<\/p>\n
Global CDMO expansion is expected to influence capacity, competition, and service availability for European therapy developers. In April 2025, ProBio launched a GMP plasmid DNA manufacturing service at its Hopewell facility, offering a three-month timeline from cell bank to batch release for clinical-grade material. In June 2024, Bionova Scientific, part of the Asahi Kasei Group, announced a US$ 100 million investment in a 100,000-square-foot plasmid DNA manufacturing facility in The Woodlands, Texas. The site was planned to begin with development and research-grade production, followed by GMP capabilities in 2026.<\/p>\n
Germany is expected to maintain a leading position in the European market due to its biotechnology expertise, industrial base, government support, and demand for gene therapies and vaccines. National programs, including the Bioeconomy Strategy and funding from the Federal Ministry of Education and Research (BMBF), are advancing life sciences research and manufacturing capabilities. Continued investment in GMP infrastructure, CDMO partnerships, and next-generation therapeutic platforms is expected to support long-term growth across the Europe DNA Plasmid Manufacturing Market.<\/p>\n
Key Topics Covered<\/p>\n
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation<\/p>\n
2. Executive Summary
2.1 Key Insights<\/p>\n
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:<\/p>\n
4. Europe DNA Plasmid Manufacturing Market – Key Market Dynamics
4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:<\/p>\n
5. DNA Plasmid Manufacturing Market – Europe Market Analysis
5.1 Europe DNA Plasmid Manufacturing Market Revenue (US$ Million), 2024 – 2031
5.2 Europe DNA Plasmid Manufacturing Market Forecast and Analysis<\/p>\n
6. Europe DNA Plasmid Manufacturing Market Revenue Analysis – by Product Type
6.1 GMP Grade
6.1.1 Overview
6.1.2 GMP Grade: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
6.2 R&D grade
6.2.1 Overview
6.2.2 R&D grade: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)<\/p>\n
7. Europe DNA Plasmid Manufacturing Market Revenue Analysis – by Application
7.1 Cell and Gene Therapy
7.1.1 Overview
7.1.2 Cell and Gene Therapy: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 DNA Vaccines
7.2.1 Overview
7.2.2 DNA Vaccines: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)<\/p>\n
8. Europe DNA Plasmid Manufacturing Market Revenue Analysis – by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 CROs and CDMOs
8.2.1 Overview
8.2.2 CROs and CDMOs: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)<\/p>\n
9. Europe DNA Plasmid Manufacturing Market – Country Analysis
9.1 Europe
9.1.1 Europe DNA Plasmid Manufacturing Market Revenue and Forecast and Analysis – by Country
9.1.2 Germany
9.1.2.1 Germany: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.1.2.2 Germany: Europe DNA Plasmid Manufacturing Market Share – by Product Type
9.1.2.3 Germany: Europe DNA Plasmid Manufacturing Market Share – by Application
9.1.2.4 Germany: Europe DNA Plasmid Manufacturing Market Share – by End User
9.1.3 United Kingdom
9.1.3.1 United Kingdom: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.1.3.2 United Kingdom: Europe DNA Plasmid Manufacturing Market Share – by Product Type
9.1.3.3 United Kingdom: Europe DNA Plasmid Manufacturing Market Share – by Application
9.1.3.4 United Kingdom: Europe DNA Plasmid Manufacturing Market Share – by End User
9.1.4 France
9.1.4.1 France: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.1.4.2 France: Europe DNA Plasmid Manufacturing Market Share – by Product Type
9.1.4.3 France: Europe DNA Plasmid Manufacturing Market Share – by Application
9.1.4.4 France: Europe DNA Plasmid Manufacturing Market Share – by End User
9.1.5 Italy
9.1.5.1 Italy: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.1.5.2 Italy: Europe DNA Plasmid Manufacturing Market Share – by Product Type
9.1.5.3 Italy: Europe DNA Plasmid Manufacturing Market Share – by Application
9.1.5.4 Italy: Europe DNA Plasmid Manufacturing Market Share – by End User
9.1.6 Spain
9.1.6.1 Spain: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.1.6.2 Spain: Europe DNA Plasmid Manufacturing Market Share – by Product Type
9.1.6.3 Spain: Europe DNA Plasmid Manufacturing Market Share – by Application
9.1.6.4 Spain: Europe DNA Plasmid Manufacturing Market Share – by End User
9.1.7 Rest of Europe
9.1.7.1 Rest of Europe: Europe DNA Plasmid Manufacturing Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.1.7.2 Rest of Europe: Europe DNA Plasmid Manufacturing Market Share – by Product Type
9.1.7.3 Rest of Europe: Europe DNA Plasmid Manufacturing Market Share – by Application
9.1.7.4 Rest of Europe: Europe DNA Plasmid Manufacturing Market Share – by End User<\/p>\n
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.2 Company Positioning & Concentration<\/p>\n
11. Industry Landscape
11.1 Overview
11.2 New Product Development
11.3 Merger and Acquisition
11.4 Other Strategic Developments<\/p>\n
12. Company Profiles
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Catalent Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 WuXi Biologics Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sartorius AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GenScript Biotech Corporation
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Takara Bio Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AGC Biologics AS
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Thermo Fisher Scientific Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SK pharmteco Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Creative Biogene
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments<\/p>\n
13. Appendix
13.1 About the Analyst<\/p>\n
List of Tables [25]<\/p>\n
List of Figures [24]<\/p>\n
For more information about this report visit https:\/\/www.researchandmarkets.com\/r\/ruzt23<\/a> <\/p>\n About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/Research-and-Markets.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"Outsourcing to scalable, GMP-compliant CDMOs helps biopharma avoid capital costs and accelerate time to market, while partnerships improve…\n","protected":false},"author":2,"featured_media":872376,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[28,112],"class_list":["post-872375","post","type-post","status-publish","format-standard","has-post-thumbnail","category-markets","tag-business","tag-markets"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/872375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=872375"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/872375\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/872376"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=872375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=872375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=872375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}